Results of SHARP study (Study of Heart and Renal Protection)

Abstract

During a median follow-up of 4.9 years in patients with CKD, Eze/Simva 10/20 mg significantly reduced the risk of first major vascular events

Keywords

• ezetimibe
• simvastatin
• chronic kidney disease